Articles related to DEPRESSION

This study underscores the potential of IV ketamine in managing major depressive disorder, especially in patients with a history of multiple antidepressant trials. With a significant percentage achieving response or remission within six weeks, and these benefits sustained over months, ketamine offers a promising avenue for chronic depression management.

In an insightful study on major depressive disorder, it was found that an increase in guideline concordance, as measured by the GCA-8 score, was associated with a notable improvement in patient-reported depression symptoms, emphasizing the need for rigorous adherence to established treatment protocols.

Escitalopram shows promising results in the acute phase treatment of major depressive disorder, offering a potentially more effective and tolerable option for patients compared to other SSRIs and newer antidepressants.

Groundbreaking research reveals ketamine’s potential as an effective alternative to ECT in treating treatment-resistant depression, offering new hope to millions.

The mental health of cancer patients is an often overlooked aspect of their care. With anxiety and depression being significantly more prevalent in this group, it’s time we pay attention.

The advent of zuranolone may be going beyond postpartum depression, with 87.5% of patients noticing improvements within the first week of treatment for MDD.